Does LEUPROLIDE Cause Second primary malignancy? 46 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 46 reports of Second primary malignancy have been filed in association with LEUPROLIDE (Fensolvi). This represents 0.1% of all adverse event reports for LEUPROLIDE.
46
Reports of Second primary malignancy with LEUPROLIDE
0.1%
of all LEUPROLIDE reports
6
Deaths
11
Hospitalizations
How Dangerous Is Second primary malignancy From LEUPROLIDE?
Of the 46 reports, 6 (13.0%) resulted in death, 11 (23.9%) required hospitalization, and 5 (10.9%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LEUPROLIDE. However, 46 reports have been filed with the FAERS database.
What Other Side Effects Does LEUPROLIDE Cause?
Hot flush (9,146)
Death (8,772)
Intercepted product preparation error (8,621)
Syringe issue (7,847)
Device leakage (5,861)
Wrong technique in product usage process (5,062)
Fatigue (4,805)
Injection site pain (4,678)
Prostatic specific antigen increased (2,432)
Asthenia (2,176)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which LEUPROLIDE Alternatives Have Lower Second primary malignancy Risk?
LEUPROLIDE vs LEVALBUTEROL
LEUPROLIDE vs LEVAMISOLE
LEUPROLIDE vs LEVAQUIN
LEUPROLIDE vs LEVEMIR
LEUPROLIDE vs LEVETIRACETAM